Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of JTM201 in Moderate or Severe Glabellar Lines
NCT06246552Phase 2Completed
- Sponsor
- JETEMA Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in glabellar lines, sponsored by JETEMA Co., Ltd.. Started Oct 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06246552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246552.